Application of the high-precision technique is part of a clinical trial to treat a genetic disease that can cause liver and ...

A personalized CRISPR treatment for a critically ill baby shows how editing, RNA manufacturing, and delivery are converging ...

A pH- and ROS-responsive hydrogel carrying CRISPR-Cas9 silenced the TRPV4 calcium channel in rat discs, restoring autophagic ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

Infant neuroblastoma is one of the most clinically paradoxical cancers in medicine. Diagnosed during the first year of life, ...

With the global population approaching 10 billion, farmers face an unprecedented challenge: doubling the world's food supply. This video breaks down the technologies, from autonomous drones and ...

CRSP’s main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It’s a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy’s rollout has been slow ...

CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand. The ...

In a historic medical breakthrough, a child diagnosed with a rare genetic disorder has been successfully treated with a customized CRISPR gene editing therapy by a team at Children's Hospital of ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...

Capitalize on ready-to-use CRISPR kits & enzymes and drug discovery demand with competitive insights, untapped market analysis, and go-to-market strategies.Dublin, Oct. (GLOBE NEWSWIRE) -- "CRISPR ...

IROS, M42’s contract research organisation, and Mammoth Biosciences announced they will conduct the UAE’s first clinical ...